Fatty liver Shionogi-ob/ob mouse: A new candidate for a non-alcoholic steatohepatitis model

Hepatology Research

Volumn 43, Issue 5, 2013, Pages 547-556

  Sugihara, Takaaki ^a   Koda, Masahiko ^a   Kishina, Manabu ^a   Kato, Jun ^a   Tokunaga, Shiho ^a   Matono, Tomomitsu ^a   Ueki, Masaru ^a   Murawaki, Yoshikazu ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Apoptosis; Fatty liver Shinogi mouse; Hepatic fibrosis; Kupffer cell; Oxidative stress

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; GENE EXPRESSION; LIPID STORAGE; LIVER FIBROSIS; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL;

EID: 84876969186     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2012.01101.x     Document Type: Article

References (27)

1. Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology 2009; 49: 306-317.
2. Chitturi S, Wong VW, Farrell G. Nonalcoholic fatty liver in Asia: firmly entrenched and rapidly gaining ground. J Gastroenterol Hepatol 2011; 26: s163-172.
3. Fan JG, Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol 2009; 50: 204-210.
4. Okanoue T, Umemura A, Yasui K, Itoh Y. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in Japan. J Gastroenterol Hepatol 2011; 26: s153-162.
5. Anstee QM, Goldin RD. Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int J Exp Pathol 2006; 87: 1-16.
6. Soga M, Kishimoto Y, Kawaguchi J etal. The FLS mouse: a new inbred strain with spontaneous fatty liver. Lab Anim Sci 1999; 49: 269-275.
7. Soga M, Kishimoto Y, Kawamura Y, Inagaki S, Makino S, Saibara T. Spontaneous development of hepatocellular carcinomas in the FLS mice with hereditary fatty liver. Cancer Lett 2003; 196: 43-48.
8. Soga M, Hashimoto S, Kishimoto Y, Hirasawa T, Makino S, Inagaki S. Insulin resistance, steatohepatitis, and hepatocellular carcinoma in a new congenic strain of Fatty Liver Shionogi (FLS) mice with the Lep(ob) gene. Exp Anim 2010; 59: 407-419.
9. Folch J, Lees M, Sloane-Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 1957; 226: 497-509.
10. Kawahara H, Takase S. Mutation of mitochondrial DNA in patients with non-alcoholic steatohepatitis. Nippon Rinsho 2006; 64: 1095-1099. (in Japanese).
11. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-2474.
12. Schuppan D, Gorrell MD, Klein T, Mark M, Afdhal NH. The challenge of developing novel pharmacological therapies for non-alcoholic steatohepatitis. Liver Int 2010; 30: 795-808.
13. Leclercq IA, Farrell GC, Schriemer R, Robertson GR. Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J Hepatol 2002; 37: 206-213.
14. Sexana NK, Ikeda K, Rockey DC, Friedman SL, Anania FA. Leptin in hepatic fibrosis: evidence for increased collagen production in stellete cells and lean littermates of ob/ob mice. Hepatology 2002; 35: 762-771.
15. Ikejima K, Takei Y, Honda H etal. Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology 2002; 122: 1399-1410.
16. Ikejima K, Okumura K, Lang T etal. The role of leptin in progression of non-alcoholic fatty liver disease. Hepatol Res 2005; 33: 151-154.
17. Takahashi M, Saibara T, Nemoto Y etal. A novel type hypertriglyceridemia observed in FLS mice. Lipids 2003; 38: 687-692.
18. Suganami T, Tanimoto-Koyama K, Nishida J etal. Role of the Toll-like receptor 4/NF-kappaB pathway in saturated fatty acid-induced inflammatory changes in the interaction between adipocytes and macrophages. Arterioscler Thromb Vasc Biol 2007; 27: 84-91.
19. Yang S, Lin H, Diehl AM. Fatty liver vulnerability to endotoxin-induced damage despite NF-kappaB induction and inhibited caspase 3 activation. Am J Physiol Gastrointest Liver Physiol 2001; 281: G382-392.
20. Tomita K, Tamiya G, Ando S etal. Tumour necrosis factor α signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. Gut 2006; 55: 415-424.
21. Barbuio R, Milanski M, Bertolo MB, Saad MJ, Velloso LA. Infliximab reverses steatosis and improves insulin signal transduction in liver of rats fed a high-fat diet. J Endocrinol 2007; 194: 539-550.
22. Crespo J, Cayón A, Fernández-Gil P etal. Gene expression of tumor necrosis factor α and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 2001; 34: 1158-1163.
23. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998; 114: 842-845.
24. Zamara E, Novo E, Marra F etal. 4-Hydroxynonenal as a selective pro-fibrogenic stimulus for activated human hepatic stellate cells. J Hepatol 2004; 40: 60-68.
25. Curzio M, Esterbauer H, Di Mauro C, Cecchini G, Dianzani MU, Seyler H. Chemotactic activity of the lipid peroxidation product 4-hydroxynonenal and homologous hydroxyalkenals. Biol Chem 1986; 367: 321-329.
26. Iwai S, Murai T, Makino S etal. High sensitivity of fatty liver Shionogi (FLS) mice to diethylnitrosamine hepatocarcinogenesis: comparison to C3H and C57 mice. Cancer Lett 2007; 246: 115-121.
27. Lee JY, Sohn KH, Rhee SH, Hwang D. Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4. J Biol Chem 2001; 276: 16683-16689.